Holen Sie sich die Stockscreener-App
10.73
10.62%
1.03
Vorhandelsmarkt:
10.69
-0.04
-0.37%
Schlusskurs vom Vortag:
$9.70
Offen:
$9.55
24-Stunden-Volumen:
83,168
Relative Volume:
1.85
Marktkapitalisierung:
$65.36M
Einnahmen:
$5.75M
Nettoeinkommen (Verlust:
$-38.96M
KGV:
-0.8605
EPS:
-12.47
Netto-Cashflow:
$-32.63M
1W Leistung:
+13.19%
1M Leistung:
+42.50%
6M Leistung:
+73.34%
1J Leistung:
+53.07%
1-Tages-Spanne:
$9.55
$10.79
1-Wochen-Bereich:
$8.87
$10.79
52-Wochen-Spanne:
$4.21
$10.79
Kala Bio Inc Stock (KALA) Company Profile
Firmenname
Kala Bio Inc
Sektor
Branche
Telefon
781-996-5252
Adresse
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Vergleichen Sie KALA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
10.73 | 65.36M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-03-30 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-14 | Herabstufung | Jefferies | Buy → Hold |
| 2020-07-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-27 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-09 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Kala Bio Inc Aktie (KALA) Neueste Nachrichten
Short Interest in KALA BIO, Inc. (NASDAQ:KALA) Rises By 19.1% - MarketBeat
KALA stock soars to 52-week high, reaching $8.81 - MSN
KALA stock soars to 52-week high, reaching $8.81 By Investing.com - Investing.com Australia
ED Attaches ₹79.78 Crore Assets In Sharon Bio-Medicine’s ₹220 Crore Bank Fraud Case - Free Press Journal
Ramesh Lal Kala , IND candidate bio : Assets , Total Income , Liabilities , Criminal Cases and other details. - The Hindu
KALA BIO Announces $10.75 Million Private Placement Agreement - WilmerHale
Kala Bio executive Todd Bazemore sells $15,206 in stock By Investing.com - Investing.com Australia
Kala Bio's head of research sells $18,662 in stock - Investing.com India
Kala Bio CEO Mark Iwicki sells $44,093 in stock - Investing.com India
Kala Bio's chief business officer sells $15,420 in stock By Investing.com - Investing.com South Africa
Kala Bio’s chief business officer sells $15,420 in stock By Investing.com - Investing.com Nigeria
Kala Bio's head of research sells $18,662 in stock By Investing.com - Investing.com South Africa
Kala Bio CFO Mary Reumuth sells $13,016 in company stock By Investing.com - Investing.com Nigeria
Kala Bio CFO Mary Reumuth sells $13,016 in company stock - Investing.com
Kala Bio's chief business officer sells $15,420 in stock - Investing.com
Baker Bros. Advisors LP Increases Stake in Kala Bio Inc - GuruFocus.com
Baker Bros. Advisors buys $2 million in Kala Bio shares By Investing.com - Investing.com Australia
KALA BIO announces $10.75M private placement - MSN
Baker Bros. Advisors buys $2 million in Kala Bio shares - Investing.com
Kala Bio raises $10.75 million in private placement By Investing.com - Investing.com Canada
KALA BIO Announces Private Placement Agreement with Institutional Investors - Defense World
KALA BIO Secures $10.75 Million in Private Placement to Advance Eye Disease Treatments - Tandav Media
Kala Bio raises $10.75 million in private placement - Investing.com India
KALA Bio Secures $10.75 Million for Eye Disease Treatments: What’s Next for the Biopharma Stock? - Tandav Media
KALA BIO Announces $10,750,000 Private Placement - GlobeNewswire
Global Engine Group Holding Limited Acquires 22.5% Stake in Corpotech Holdings Limited, a Hong Kong Data Centre Operator - The Manila Times
KALA BIO Secures $10.75M Investment from Major Funds, Extends Cash Runway for Key Eye Treatment Trial - StockTitan
Exicure joins hands with GPCR Therapeutics for growth in biotech (NASDAQ:XCUR) - Seeking Alpha
RBC Capital Downgrades HOOKIPA Pharma (HOOK) - MSN
KALA BIO (KALA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Zacks Investment Research
PepGen stock down 22% on FDA clinical hold (update) (PEPG:NASDAQ) - Seeking Alpha
Tracking Baker Brothers Portfolio – Q3 2024 Update - Seeking Alpha
Kala Bio (LTS:0JQ2) EV-to-Revenue : (As of Nov. 30, 2024) - GuruFocus.com
KALAKALA BIO, Inc. Latest Stock News & Market Updates - StockTitan
FTC Solar Announces Reverse Stock Split - The Manila Times
KALA BIO to Present at Piper Sandler Healthcare Conference, Showcasing Eye Disease Pipeline | KALA Stock News - StockTitan
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
2024 Pharmaceutical Executive APEX Award Winners - Pharmaceutical Executive
Kala Pharmaceuticals Announces IND Submission of its MPP-Formulated Loteprednol Etonbonate (LE-MPP) for Post-Cataract Surgery - Marketscreener.com
Kala Pharmaceuticals retains stock target with Buy rating on trial progress - Investing.com India
60 Degrees Pharmaceuticals’ (SXTP) Neutral Rating Reaffirmed at HC Wainwright - Defense World
Walt Disney (NYSE:DIS) Price Target Raised to $130.00 - Defense World
KALA BIO’s (KALA) Buy Rating Reaffirmed at HC Wainwright - Defense World
ADAR1 Capital Management, LLC Increases Stake in Kala Bio Inc - GuruFocus.com
Finanzdaten der Kala Bio Inc-Aktie (KALA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kala Bio Inc-Aktie (KALA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Brazzell Romulus K | SEE REMARKS |
Jan 06 '25 |
Sale |
7.63 |
2,446 |
18,663 |
92,418 |
| Iwicki Mark T | CHIEF EXECUTIVE OFFICER |
Jan 06 '25 |
Sale |
7.63 |
5,779 |
44,094 |
280,076 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Jan 06 '25 |
Sale |
7.63 |
1,706 |
13,017 |
68,581 |
0.82%
0.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):